CELLPOINT
CellPoint Digital , a leading global provider of Digital Commerce and Payment Orchestration solutions, today announces a new partnership with Virgin Atlantic and Virgin Holidays .
The airline and holiday package provider will use CellPoint Digital’s full payment orchestration platform to seamlessly integrate new payment methods, new acquirers and stored card facilities, enabling reduced costs, increased acceptance rates and a better customer experience.
By orchestrating payments across regions and payment methods, CellPoint Digital’s innovative platform allows merchants to adopt a multi-acquirer payments model that opens new opportunities for growth. It also helps increase top-line revenue utilising intelligent routing, increasing authorisations, and providing system uptime transparency, and reduces the operation cost of accepting cross border payments.
News of the Virgin deal comes after a series of investments by Toscafund and Penta Capital into CellPoint Digital, which brings their total investment to more than $56M.
Yasin Demir, head of distribution and payments at Virgin Atlantic, added: “We identified CellPoint Digital as specialists in payment orchestration, providing a unique and innovated mind set towards the airline payments ecosystem. Its offering aligns perfectly with our plans to add multiple new acquirers and payment methods and we are looking forward to working with them in the coming months and beyond.”
Kristian Gjerding, CEO at CellPoint Digital, commented: “Virgin is one of the largest carriers in the UK and we are excited to be working with a brand that has such an incredible global reputation. As the project progresses, we will be collaborating closely with the Virgin payments team to ensure they get maximum benefit from our payment orchestration platform.
“By utilising our comprehensive payment orchestration platform and having access to a large payments ecosystem, we can enhance the payment process for Virgin Atlantic and Holidays while bolstering its offering with popular alternative payment methods for its customers.
Our Payment Orchestration Platform will give Virgin access to a much larger payment ecosystem and enable it to offer customers their preferred method of payment for the countries it flies to. As we emerge from the pandemic, fewer travellers are using cards to purchase tickets, with the convenience of mobile devices, e-wallet options and QR codes transforming the way they pay for airline tickets. Recent research has highlighted that 84% of travellers now pay with alternative payment methods.”
CellPoint Digital’s powerful omni-channel Payment Orchestration Platform optimises digital payment transactions, from cards or alternative payment methods, and accelerates the deployment of new payment options. Users can easily scale their own payment ecosystem across the world, unify the customer payment experience across their website, mobile apps and other channels, optimise the routing of each transaction, increase conversion rate and minimise payment costs.
To find out more, visit https://cellpointdigital.com/
ENDS
About CellPoint Digital
CellPoint Digital is a fintech leader in payment orchestration. CellPoint Digital’s main solution is a powerful omni-channel Payment Orchestration Platform that optimises digital payment transactions, from cards or alternative payment methods, and accelerates the deployment of new payment options. Merchants can easily scale their own payment ecosystem across the world, unify the customer payment experience across their website, mobile apps and other channels, optimize the routing of each transaction, increase conversion rates and minimise payment costs. Toscafund and Penta Capital have invested more than $56 million into CellPoint Digital.
CellPoint Digital has offices in Copenhagen, Dallas, Dubai, London, Miami, Pune and Singapore.
About Virgin Atlantic
Virgin Atlantic first took to the skies in 1984, instantly shaking things up and attracting plenty of attention. Since then Virgin Atlantic has become the UK’s second largest carrier, helping customers to fly and connect all around the world, with non-stop transatlantic routes including New York, Los Angeles, Hong Kong, Delhi and Johannesburg. Plus, thanks to the joint venture with Delta, Air France and KLM, over 350 cities across North America, Europe and the UK have now become accessible.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220327005040/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom